TA
GILD icon

Townsend & Associates’s Gilead Sciences GILD Stock Holding History

Townsend & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,152
Closed -$1.32M – 112
2023
Q2 		$1.32M Sell
17,152
-1,669
-9% -$133K 0.34% 66
2023
Q1 		$1.55M Sell
18,821
-11,288
-37% -$935K 0.62% 60
2022
Q4 		$2.63M Sell
30,109
-405
-1% -$32.1K 1.3% 28
2022
Q3 		$2.51M Buy
30,514
+1,497
+5% +$94.4K 1.16% 25
2022
Q2 		$1.82M Buy
29,017
+2,250
+8% +$139K 0.84% 40
2022
Q1 		$1.67M Buy
26,767
+2,774
+12% +$177K 0.77% 52
2021
Q4 		$1.72M Buy
+23,993
New +$1.65M 0.94% 46

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Townsend & Associates's GILD Position: Q3 2023 in Review

Townsend & Associates sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 17,152 shares — an estimated $1.32M sold.

Townsend & Associates first reported a position in GILD in Q4 2021 and held it in 7 quarters. The position peaked at $2.63M in Q4 2022. 1,682 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

  • Townsend & Associates reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
  • Townsend & Associates sold 17,152 Gilead Sciences shares in Q3 2023, an estimated $1.32M.
  • Townsend & Associates first reported a position in Gilead Sciences in Q4 2021 and held it in 7 quarters.
  • Townsend & Associates's Gilead Sciences position peaked at $2.63M in Q4 2022.
  • 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Townsend & Associates's 13F filing for Q3 2023, filed 1 Nov 2023.